IOVANCE BIOTHERAPEUTICS

iovance-biotherapeutics-logo

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.
#SimilarOrganizations #People #Financial #Website #More

IOVANCE BIOTHERAPEUTICS

Social Links:

facebook

Facebook

linkedin

Linkedin

Industry:
Biotechnology Health Care Medical

Founded:
2007-01-01

Address:
New York, New York, United States

Country:
United States

Website Url:
http://www.iovance.com

Total Employee:
251+

Status:
Active

Contact:
(212)946-4856

Total Funding:
1.22 B USD

Technology used in webpage:
IPv6 GoDaddy DNS COVID-19 Akamai Hosted Rackspace


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

elicio-therapeutics-logo

Elicio Therapeutics

Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.

gracell-biotechnologies-logo

Gracell Biotechnologies

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

harpoon-therapeutics-logo

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.

Current Employees Featured

igor-bilinsky_image

Igor Bilinsky
Igor Bilinsky Chief Operating Officer @ Iovance Biotherapeutics
Chief Operating Officer
2021-03-01

not_available_image

John Schick
John Schick Vice President, Market Access & Policy, Cell Therapy @ Iovance Biotherapeutics
Vice President, Market Access & Policy, Cell Therapy
2020-05-01

sandy-mohan_image

Sandy Mohan
Sandy Mohan Vice President, Quality @ Iovance Biotherapeutics
Vice President, Quality
2019-09-01

not_available_image

Timothy E. Morris
Timothy E. Morris Chief Financial Officer @ Iovance Biotherapeutics
Chief Financial Officer

maria-fardis_image

Maria Fardis
Maria Fardis President & Chief Executive Officer @ Iovance Biotherapeutics
President & Chief Executive Officer
2016-06-01

Founder


manish-singh_image

Manish Singh

Stock Details


Company's stock symbol is NASDAQ:IOVA

Acquisitions List

Date Company Article Price
2013-10-31 Genesis Biopharma Genesis Biopharma acquired by Iovance Biotherapeutics N/A

Investors List

orbimed-advisors_image

OrbiMed

OrbiMed investment in Post-IPO Equity - Iovance Biotherapeutics

broadfin_image

Broadfin Capital

Broadfin Capital investment in Post-IPO Equity - Iovance Biotherapeutics

quogue-capital_image

Quogue Capital

Quogue Capital investment in Post-IPO Equity - Iovance Biotherapeutics

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Post-IPO Equity - Iovance Biotherapeutics

Official Site Inspections

http://www.iovance.com Semrush global rank: 616.87 K Semrush visits lastest month: 72.59 K

  • Host name: server-3-162-125-4.iad61.r.cloudfront.net
  • IP address: 3.162.125.4
  • Location: Seattle United States
  • Latitude: 47.6348
  • Longitude: -122.3451
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98109

Loading ...

More informations about "Iovance Biotherapeutics" on Search Engine

dfkcompany.com © 2022. All rights reserved